Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Takeda: PharmaVitae Profile' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile |
February 2009 | £3010 | 100 % |
|
Takeda IMS Company Profile |
June 2008 | £510 | 70 % |
|
Takeda Pharmaceutical Company Limited - SWOT Analysis |
January 2009 | £66 | 35 % |
|
Millennium Pharmaceuticals SWOT Analysis |
November 2008 | £66 | 35 % |
|
Takeda Pipeline, Products,Performance,Potential |
October 2008 | £595 | 33 % |
|
Millennium Pharmaceuticals, Inc. - SWOT Analysis |
November 2008 | £66 | 31.5 % |
|
Takeda Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 26.6 % |
|
Takeda Pharmaceutical Co., Ltd Pharmavitae Profile |
December 2007 | £3010 | 21.35 % |
|
Takeda Partnering Guide 2008 |
July 2008 | £195 | 18.9 % |
|
Schering-Plough Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 17 % |
|
Innovations in The Management of Diabetes Next generation treatments and market dynamics |
June 2008 | £1995 | 15.4 % |
|
Tanabe Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 14 % |
|
NRT Smoking Cessation Aids in Japan |
June 2006 | £450 | 14 % |
|
The Top 50 Pharmaceutical Manufacturing Companies In Ireland |
September 2005 | £285 | 14 % |
|
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £1955 | 13.3 % |
|
Johnson & Johnson PharmaVitae Profile |
July 2008 | £3010 | 9.8 % |
|
Johnson & Johnson: PharmaVitae Profile Healthcare |
March 2009 | £3010 | 9.8 % |
|
Obesity Drug Discoveries: what the future holds |
August 2007 | £1425 | 9.5 % |
|
Eye Care in Japan |
September 2007 | £450 | 9.45 % |
|
Medicated Skin Care in Japan |
September 2007 | £450 | 9.45 % |
|
Astellas Pharma Inc.: PharmaVitae Profile |
February 2009 | £3010 | 9.1 % |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1525 | 7 % |
|
Bigpharma Dealmaking and Agreements Handbook 2007 Companies, Contacts & Partnering Agreements |
September 2007 | £1195 | 7 % |
|
Bigpharma Dealmaking Handbook Companies & Contacts |
September 2008 | £1195 | 7 % |
|
Commercial Insight: Antihormonal Therapy Cancer Brands Careful Lifecycle Management Needed to Preserve Brand Dominance |
August 2008 | £7600 | 6.65 % |
|
Partnering with Biopharma The definitive guide to bigpharma partnering interests, contacts & agreements |
July 2008 | £1495 | 6.3 % |
|
Sleep Disorders Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking |
March 2009 | £2075 | 4.9 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1670 | 4.55 % |
|
Osteoporosis & Bone Metabolism Disorders Market 2008-2023 |
August 2008 | £1499 | 4.2 % |
|
World Gastrointestinal Disorders Market 2008-2023 |
October 2008 | £1499 | 3.85 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £6000 | 3.85 % |
|
Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
November 2008 | £8000 | 3.5 % |
|
Drug Delivery Technology: Revolutionizing CNS Therapies |
December 2007 | £945 | 3.5 % |
|
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies |
November 2008 | £8000 | 3.5 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £8000 | 2.8 % |
|
CNS Drug Discoveries What the Future Holds |
November 2006 | £1995 | 2.8 % |
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries |
July 2007 | £7600 | 2.1 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £2960 | 1.75 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £6000 | 1.75 % |
